169 results about "Lymphatic vessel" patented technology

The present invention provides a lipid nanoparticle used for delivering a nucleic acid to a lymphatic endothelial cell, including an ionic lipid represented by the formula (1), cholesterol, and a dimyristoylglycerol PEG with a number average molecular weight of PEG chain of 1,000 to 3,000, wherein an amount of the dimyristoylglycerol PEG is not less than 3 mol % with respect to the total of the ionic lipid represented by the formula (1) and the cholesterol (the symbols in the formula (1) are as defined in the specification).

A contrast agent for imaging lymph nodes or lymphatic vessels with near-infrared light that can selectively image primary lymph nodes relative to secondary or higher lymph nodes. A dose of the composition suitable for imaging lymph nodes or lymphatic vessels.

Some embodiments of the invention advantageously leverage the expansion, dilation or by-pass of the Schlemm's canal using adjustable reversible self-expanding eye stents (SES) or eye tension rings (ETRs) of desired sizes to control and improve aqueous flow throughout the range of the uveolymphatic canal. As such, some embodiments include tension ring(s) or cylinders that sits either inside or outside the Schlemm's canal wall and is at least partially within the canal and / or is partially or fully anchored, attached, adhered, or otherwise held in place with respect to the wall and / or elsewhere in the canal. The partial or complete expansion of the canal can be pre-configured based on pre-operative metrology of the Schlemm's canal to a customized and adjustable fit across the various zones within the uveolymphatic canal and based on the patient specific and evolving needs. Additionally, the SES can utilize entry / exit features for by-pass of fluid, varying control of dilation across its shape that may also allow anchoring, repositioning, and retrieval.

The invention belongs to the technical field of medical data processing, and particularly relates to a bladder cancer vessel tumor embolus assessment method and system based on multi-modal feature fusion, and the optimization method comprises the steps: obtaining and preprocessing the pathological information and image data of a bladder cancer patient, extracting a CT image corresponding to a tumor, and determining a region of interest; image omics features are extracted from the region of interest of the CT image, and deep learning features are extracted from the maximum tumor cross section; carrying out feature selection processing on the obtained radiomics features and deep learning features, and inputting the processed features into a fusion model; and outputting a probability value of'lymphatic vessel invasion 'by the fusion model to obtain an evaluation result. A multi-modal machine learning model is constructed by fusing radiomics features and deep learning features extracted from a CT image, and the objective of the invention is to noninvasively and accurately evaluate the lymphatic vessel infringement state of bladder cancer before an operation, so that a key basis is provided for clinical individualized treatment decision-making.

The invention discloses a modular tumor microenvironment response polypeptide and a preparation method and application thereof. The modular tumor microenvironment response polypeptide is composed of the following functional modules: a targeting and chemotactic module used for targeting tumor cell surface p32 protein and tumor lymphatic vessels and promoting tumor tissue penetration and enrichment; the microenvironment double-response module is used for being cut by MMP-2 / 9 enzyme and broken by high-concentration glutathione GSH in a tumor microenvironment to trigger self-assembly; the self-assembly driving module is used for exposing after the microenvironment responds to activation and driving short peptides to be self-assembled to form a nano structure; a killing module: a pro-apoptotic peptide PAD used for targeting a mitochondrial membrane and inducing tumor cell apoptosis; and the stability optimization module is used for enhancing the degradation resistance of the oligopeptide. By integrating targeted delivery, enzyme digestion response, acid-sensitive release and stabilizing structures, the problems of insufficient targeting property, inaccurate release, poor stability, diagnosis-treatment splitting and the like of the anti-tumor drug and the developing agent are solved.

The invention relates to a gynecological pelvic and abdominal lymphatic cleaning prediction model training method and a lymph node model.The training method comprises the steps that preoperative image data and intraoperative instrument operation parameters of historical patients are subjected to modeling processing, and a dynamic mechanics-fluid coupling lymph node model based on bionic materials is constructed; mechanical deformation and fluid flow of a lymphatic system in various clinical scenes are simulated; performing data acquisition processing on the used lymph node model, and quantifying the dynamic influence of the surgical operation on the lymphatic system; the relevance between historical operation and injury risk is deeply learned, and the lymphatic vessel rupture probability is output; real-time feedback control processing is carried out based on the lymphatic vessel rupture probability, a training correction instruction and a risk thermodynamic diagram are generated, and medical workers are guided to optimize surgical skills. Through fusion analysis of the high-fidelity bionic model and multi-modal data, dynamic simulation of the mechanical-fluid coupling effect in the operation and real-time quantification of the operation risk are achieved, and the accuracy and clinical transformation value of operation training are improved.

The invention belongs to the technical field of biomedical functional dyes and probes, and relates to a fluorescent probe, in particular to a cyclodextrin-based near-infrared fluorescent probe, which is a conjugate formed by coating a fluorescent molecule with cyclodextrin. According to the near-infrared fluorescent probe disclosed by the invention, cyclodextrin is nested on a carbon chain of a fluorescent molecule, so that the water solubility, histocompatibility and safety are improved, the fluorescence lifetime is prolonged, the light stability is improved, and rapid transmission and response of ureters, lymphatic vessels and lymph nodes in vivo are realized; the method can be used for NIR-I and NIR-II imaging; a near-infrared fluorescence probe with targeting property can be formed by marking various tumor targeting molecules, so that accurate targeting fluorescence imaging of different types of tumors such as urogenital tumors, head and neck cancers, breast cancers and cervical cancers and metastatic lymph nodes in NIR-I and NIR-II windows is realized, and the near-infrared fluorescence probe can be applied to fluorescence imaging navigation in clinical operations.

The invention relates to a model for predicting an early gastric cancer lymph node metastasis risk and a construction method and application thereof. The input variables of the model comprise gender, tumor position, tumor maximum diameter, pathological differentiation degree, pT staging condition, submitted lymph node number and lymphatic vessel invasion condition, and the output value of the model is lymph node metastasis prediction probability. A model for predicting the lymph node metastasis risk of the early gastric cancer is designed, the lymph node metastasis risk of a patient with the early gastric cancer can be accurately evaluated through the model, a model for predicting the number of the lymph node metastasis is further obtained, a corrected pN stage (pNM) is provided based on the predicted number of the lymph node metastasis, and the establishment of the pNM stage can be used for predicting the lymph node metastasis risk of the patient with the early gastric cancer. The method can be applied to diagnosis of early gastric cancer patients who cannot perform sufficient lymph node cleaning due to various reasons, is helpful for clinicians to evaluate and calculate early gastric cancer patients who do not reach the sufficient number of detected lymph nodes, and provides a new way for accurate clinical evaluation.

A lymphangiogenesis inducing device includes: a puncture member comprising a distal end portion configured to puncture living tissue, and a through hole penetrating the puncture member along a central axis and extending from the distal end portion toward a proximal end; and a rod-shaped body inserted into the through hole and configured to be moved so as to protrude from the distal end portion. The rod-shaped body comprises a shaft portion, and a wound imparting structure comprising at least one protrusion located on the shaft portion and configured to impart a wound to the living tissue. The at least one protrusion has a protruding height from the shaft portion that increases when the at least one protrusion transitions from a state in which the at least one protrusion is located in the through hole to a state in which the at least one protrusion is located outside the through hole.

Article of clothing (3, 12) for stimulating lymph flow in a body area (1, 11) of a wearer (2) with having a basic body (4, 13) a multitude of protrusions (8) which are arranged on an inside (9) of the garment (3, 12), wherein the projections (8) are arranged such that they form at least one track (7, 16), wherein at least one pathway (7, 16) runs along at least one lymphatic pathway of a carrier (2), characterized by that the basic body (4, 13) comprises diagonally and / or counter-rotating elastic fiber strands and that the projections (8) are point-shaped and / or have a circular cross-section and form part of a spherical sphere, wherein the projections (8) have a height (H) between 0.5 mm and 2 mm and / or a diameter (D) between 0.5 mm and 3 mm and / or a distance (A) of 0.5 cm to 1.5 cm from each other along the at least one track (7, 16).

Provided is an effective agent for the treatment of intractable lymphangiopathy and intractable vascular disease. A therapeutic agent for intractable lymphatic diseases and intractable vascular diseases, which contains sirolimus as an active ingredient, and which is administered orally or via a tube at an administration amount that is determined on the basis of parameters associated with the in-vivo dynamics of sirolimus in a patient suffering from the diseases and the body weight and month age of the patient.

A method of forming a wound for inducing lymphangiogenesis includes: providing a lymphangiogenesis inducing device that includes: a puncture member including a distal end portion configured to puncture living tissue, and a through hole penetrating the puncture member along a central axis and extending from the distal end portion toward a proximal end, and a rod-shaped body inserted into the through hole and configured to be moved so as to protrude from the distal end portion, where the rod-shaped body includes a shaft portion, and a wound imparting structure; puncturing the living tissue with the lymphangiogenesis inducing device while the rod-shaped body is located in the through hole; passing the lymphangiogenesis inducing device through a regeneration route; pulling back the puncture member while the rod-shaped body is left in the living tissue; and pulling back the rod-shaped body.

The invention discloses a B ultrasonic guided lymphangioma simulated sclerosis injection treatment training model set, which belongs to the technical field of treatment training models, and comprises a sterile bag and a support plate, and the top end of the support plate is provided with a model main body placing groove, a needle cylinder placing groove, a lymphatic simulation liquid bottle placing groove, a capsule body model placing groove and a scalp needle placing groove. A hemispherical silica gel model main body is placed in the model main body placing groove, an elastic clamping block is fixedly connected in the needle cylinder placing groove, a needle cylinder is clamped and connected in the elastic clamping block, bag body models are placed in the bag body model placing grooves, and scalp needles are placed in the scalp needle placing grooves; lymphatic simulation liquid bottles are respectively placed in the lymphatic simulation liquid bottle placing grooves. Through the arrangement of the hemispherical silica gel model main body, the needle cylinder, the lymphatic simulation liquid bottle, the capsule body model and the scalp needle, students can visually learn how to simulate lymphangioma simulation sclerosis injection treatment training operation under the guidance of B ultrasound, observation and learning are facilitated, and rapid mastering is easy.

The present invention relates to the application of CircRAB3IP in the preparation of drugs for treating heart failure, belonging to the field of biomedical technology. The present invention provides the application of CircRAB3IP in the preparation of drugs for preventing or treating heart failure, myocardial fibrosis, myocarditis or promoting lymphangiogenesis; provides the application of CircRAB3IP in the preparation of a prognostic diagnostic kit for heart failure. Through the present invention, it is disclosed that CircRAB3IP is involved in the regulation of lymphangiogenesis and has a protective effect on the heart in hypertensive cardiac remodeling; through the present invention, the cardiac dysfunction caused by hypertensive mechanical stress can be effectively improved, cardiac remodeling and myocardial fibrosis can be slowed down, and cardiac inflammation can be reduced; a new target for the treatment of hypertensive cardiac remodeling is provided.

The invention discloses a decellularized artificial lymph drainage tube and a preparation method and application thereof, and the preparation method of the decellularized artificial lymph drainage tube comprises the following steps: taking an animal blood vessel as a raw material, and performing decellularization treatment, cleaning treatment, enhancement treatment, hole forming treatment and drying treatment on the raw material. The decellularized artificial lymph drainage tube prepared by the preparation method can solve the problems of long consumed time and difficult operation of the existing lymphatic vessel-vein anastomosis operation, can drain the lymph at the swelling part of a patient to the vein system in time after implantation, and can quickly relieve the swelling symptom. The decellularized artificial lymph drainage tube supports ingrowth, migration and proliferation of autologous cells and is good in biocompatibility, the degradation time can be adjusted to be matched with the reconstruction time of an autologous lymphatic reflux system, and long-term patency is guaranteed.

The invention discloses a human body model, and relates to the technical field of teaching instruments, and the human body model comprises a first model frame which is provided with a plurality of first meshes and is used for simulating a human body skeleton; the second model frame is provided with a cavity, a first connecting part, a second connecting part and a plurality of second meshes, the first model frame is arranged in the cavity and detachably connected with the second model frame, the first connecting part is detachably connected with the second connecting part, the second model frame is used for simulating the outer contour of a human body, and the aperture of at least part of the second meshes is larger than that of the first meshes; each of the first model frame and the second model frame comprises at least one of a head and neck, a thorax, an abdomen, a pelvis and four limbs and is correspondingly arranged; the simulation structure comprises a first simulation piece and a second simulation piece, and the first simulation piece is used for simulating blood vessels, nerves and lymphatic vessels; the second simulation piece is used for simulating human muscles and organs. The problem that in the prior art, a human body model used for teaching is difficult to operate manually while the internal structure is visualized is solved.

The invention discloses an oral cancer diagnosis model construction method, which is based on DeepLabv3 +, increases an auxiliary branch to provide position information for a diagnosis model and increases SCConv attention so as to realize segmentation processing of oral cancer multi-tissue category pathological images. The method comprises the following steps: acquiring sample set labeling data sets ORA-TCGA and ORA-Nine for training a diagnosis model, classifying data set tissues into tumors, epithelium, interstitial substances, lymphatic vessels, skeletal muscles and vessels, and performing diagnosis model training and prediction by using OCMS-Net. The diagnosis model is based on OCMS-Net and comprises a main branch A and an auxiliary branch B, the input of the main branch A is an oral cancer pathological image, the output of the main branch A is a segmentation mask, and the segmentation mask represents different tissue types with different colors; the input of the auxiliary branch B is an oral cancer pathological image, and the output of the auxiliary branch B is a binary segmentation map and a nuclear pixel distance map of a cell nucleus.

In some embodiments herein, methods, compositions, and uses for countering the effects of aberrant meningeal lymphatic drainage and / or modulating lymphatic vessels of the central nervous system are described. In some embodiments, methods, compositions, or uses for treating, preventing, or ameliorating symptoms of a neurodegenerative disease associated with aberrant meningeal lymphatic drainage are described. Modulating lymphatic vessels, or countering the effects of aberrant meningeal lymphatic drainage, in accordance with some embodiments, are used to diagnose, treat, prevent, or ameliorate symptoms of neurodegenerative diseases such as Alzheimer's disease (AD) and dementia. Methods of diagnosing and monitoring the progression of neurological diseases are also provided.

The present invention relates to a non-vascular injection formulation comprising nanoparticles, the hydrodynamic diameter of which is adjusted to 2 to 20 nm and the surface charge of which is adjusted to-20 to 0 mV by hydration of hydrophilic functional groups exposed on the surface of the nanoparticles such that the nanoparticles do not permeate into or expel into the capillaries of the administration site, the nanoparticles are only selectively excreted into the peripheral lymphatic vessel, but only selectively excreted into the peripheral lymphatic vessel, wherein the nanoparticles: (i) themselves are therapeutic agents; and / or (ii) a carrier for other drugs, thereby providing a drug form in which the nanoparticles are expelled only into the peripheral lymphatic vessel when injected into a tissue region without intravenous administration, thereby extending the residence time at the injection site. Nanoparticles having adjusted hydrodynamic diameter and surface charge according to the present invention can be excreted from the body within a week after administration without any residue at the site of administration, when designed as contrast agents exhibiting a T1MRI contrast effect and injected into tissues in the vicinity of the blood vessel, the nanoparticles can be used as contrast agents that exhibit a T1MRI contrast effect. Peripheral and / or central lymphatic vessels may be selectively imaged without venous contamination.

The invention belongs to the technical field of organ cores, and provides a brain lymphatic circulation reflux system multi-organ cascade chip model construction method and a model, and the method comprises the following steps: adjusting the size of a channel inlet and outlet of a brain lymphatic chip to be consistent with the size of a middle channel inlet of a meningeal lymphatic chip; the size of an outlet of a middle channel of the meningeal lymphatic vessel chip is adjusted to be consistent with the size of an inlet of a channel of the deep cervical lymph node chip; corresponding outlets and inlets of the brain lymphatic chip, the meningeal lymphatic vessel chip and the deep cervical lymph node chip are communicated through catheters, series connection of the three chips is achieved, the flowing process is consistent with the cerebrospinal fluid lymphatic circulation backflow process, and the blank that the cerebrospinal fluid lymphatic circulation backflow process cannot be achieved in vitro before is filled up. Moreover, the brain lymphatic chip, the meningeal lymphatic vessel chip and the deep cervical lymph node chip are cascaded to one substrate, so that the actual sizes of the three chips are reduced, and the cascade operation of multiple chips is more convenient.

The invention patent is titled "Dragon and Cypress Gel," belonging to the pharmaceutical category. The main components of Dragon and Cypress Gel are: Phellodendron bark, earthworm, dragon's blood, Oldenlandia diffusa, Sophora flavescens, and Bletilla striata. In recent years, research on cervicitis and cervical lesions has shown good results using external treatments of traditional Chinese medicine. Vaginal cervical medications are characterized by high local drug concentration, low dosage, and safety and effectiveness, receiving high clinical evaluation. The vagina and cervix have abundant capillaries and lymphatic vessels, and lack clearly defined nerve endings, resulting in minimal pain stimulation for patients during administration. This makes it an effective drug release site for specific diseases such as cervicitis and vaginitis. Traditional Chinese medicine gels are a novel type of external preparation of traditional Chinese medicine. They are made by dissolving or uniformly dispersing traditional Chinese medicine in a gel. These gels adhere tightly to the treatment site for a relatively long time, exhibiting good bioadhesion, and are simple to prepare. It is suitable for use on skin, mucous membranes and cavities. It not only avoids the first-pass effect of enzymes and acids in the gastrointestinal tract that exists in oral administration, but also reduces the adverse reactions of drugs. It has the characteristics of good spreadability, non-greasy feeling, easy to wash off, good transdermal absorption, and comfortable use.

The invention discloses an anastomosis instrument for connecting multiple lymphatic vessels and blood vessels. The anastomosis instrument comprises a blood vessel connecting piece and a plurality of lymphatic connecting tubes. According to the integrated anastomosis instrument, the multiple lymphatic vessels can be connected to the lymphatic connecting tubes respectively through the arrangement of the integrated anastomosis instrument with the multiple lymphatic connecting tubes, and the lymphatic vessels are finally guided into the same vein blood vessel through the through holes; therefore, an efficient connection mode of multiple lymphatic vessels and a single blood vessel is realized, the surgical operation is greatly simplified, the surgical time is shortened, the surgical difficulty is greatly reduced, and the risks of postoperative bleeding, inflammation and vascular stenosis are reduced; in addition, due to the establishment of a plurality of drainage channels, the total drainage efficiency of lymph is effectively improved, and the device is more suitable for clinical conditions with large lymphatic load.

The invention provides a subdural hematoma targeted drug delivery system, a preparation method thereof and a pharmaceutical preparation, and belongs to the technical field of targeted drugs. The targeted drug delivery system is a drug-loaded liposome, and the drug-loaded liposome comprises a drug active substance and a liposome carrier loaded with the drug active substance; the liposome carrier is prepared from the following components: cholesterol, lecithin, DSPE-PEG (Distearoyl Phosphate Polyethylene-Polyethylene Glycol) and DSPE-PEG-CLTX. The targeted drug delivery system provided by the invention is spherical, small and uniform in particle size, negatively charged on the surface and good in serum stability, can deliver the drug to the subdural hematoma part in a targeted manner, reduces systemic toxicity of the drug, inhibits pyroptosis, relieves inflammatory response, promotes hematoma absorption and meningeal lymphatic vessel drainage, and has a good application prospect. And the purpose of accurate treatment is achieved.

A photoacoustic flow cytometry (PAFC) device for the in vivo detection of cells circulating in blood or lymphatic vessels is described. Ultrasound transducers attached to the skin of an organism detect the photoacoustic ultrasound waves emitted by target objects in response to their illumination by at least one pulse of laser energy delivered using at least one wavelength. The wavelengths of the laser light pulse may be varied to optimize the absorption of the laser energy by the target object. Target objects detected by the device may be unlabelled biological cells or cell products, contrast agents, or biological cells labeled with one or more contrast agents.

To provide a method for reducing cholesterol.SOLUTION: There is provided an agent which promotes expression of a class B scavenger receptor which is expressed on a lymphatic vessel endothelial cell. The expression decreases with age. More specifically, at least one plant extract selected from the group consisting of a camellia seed extract, a rosemary extract, a Chinese blackberry tea extract, and a citrus unshiu peel extract is identified as a component which promotes the expression of the class B scavenger receptor, resulting in provision of an expression promoter for the scavenger receptor.SELECTED DRAWING: Figure 1

The present invention discloses a recombinant adeno-associated virus (AAV lungX-PDPN) that overexpresses KLF6 in lymphatic vessels and reduces pulmonary blood pressure. promoter ‑hKLF6), lowering pulmonary artery pressure by improving lymphatic function. Compared with existing technologies, the rAAV vector of this invention has higher targeting, more sustained expression, and lower immunogenicity, providing stable and long-lasting therapeutic effects, filling the gaps in targeting and safety in gene therapy for pulmonary arterial hypertension.

The present disclosure relates to an apparatus and method for early evaluation of lymphedema occurrence by determining the regularity of lymphatic contractions, the apparatus comprising a memory for storing at least one instruction for early evaluation of lymphedema occurrence, and a processor for performing operations according to the instruction, wherein the processor: monitors, by using indocyanine green lymphography, the occurrence of lymphedema in an animal model in which lymph nodes have been resected to disconnect lymphatic circulation in an upper limb from the proximal region; measures lymphatic contraction signals at a distal site to detect the onset of and changes in lymphatic circulation disorder; compares the measured lymphatic contraction signals with the lymphatic contraction signals from a normal site; monitors changes in the lymphatic contraction signals at the distal site; and determines the presence of lymphedema on the basis of the monitoring results.

Organ-on-chip system, including a bio-engineered lung region that is functionally connected to a bio-engineered lymphatic region via a functionalized connection region. The bio-engineered lung region includes cultured or transplanted lung cells / tissue, which can mimic in vivo lung function, and the bio-engineered lymphatic region includes lymphatic cells / tissue, which can mimic in vivo lymphatic function. The connection region allows for stimuli and cell secretions to be transported between the lung region and the lymphatic region to confer immune competency to the lung region, as the lymphatic region can generate an immune response based on stimuli received from the lung region, for example, in response to infections or therapeutic agents

The application belongs to the technical field of biological medicine, and provides an application of H151 in preparation of a medicine for treating lymphatic vessel dysfunction, wherein the application uses the STING protein antagonist H151 to treat the lymphatic vessel dysfunction, shows that H151 can significantly inhibit the activation of the cGAS-STING signal path, and then inhibit the secretion of inflammatory factors in the lymphatic endothelial cell, and effectively improve the function of the lymphatic endothelial cell. Therefore, the application uses the STING protein antagonist H151 to treat the lymphatic vessel dysfunction related diseases, opens a new way and method, and effectively solves the problem that the lymphatic vessel dysfunction lacks effective treatment means at present.